Expanding operational and regulatory expertise to support commercialization and growth

Plus Therapeutics (NASDAQ: PSTV) today announced two key leadership additions to CNSide Diagnostics, its wholly-owned subsidiary, further strengthening the company’s operational foundation as CNSide advances the commercialization of its CNS oncology diagnostic platform.

The new appointments significantly expand CNSide’s depth of expertise in laboratory operations, quality systems, and regulatory compliance, critical pillars for scalable growth in clinical diagnostics.

Prem Gurnani Joins as Senior Director of Lab Operations & Systems Implementation

Prem Gurnani brings more than 16 years of experience in diagnostics, clinical operations, regulatory compliance, and technology-driven process improvement across high-growth healthcare organizations and laboratory environments.

His background includes:

• Scaling laboratory operations
• Implementing advanced laboratory systems
• Driving operational efficiency and automation
• Supporting regulatory and compliance initiatives

Mr. Gurnani’s expertise will play a central role in supporting CNSide’s operational scale-up and commercialization roadmap.

Elaine Luckey Appointed Director of Quality & Regulatory Affairs

Elaine Luckey joins CNSide with more than 20 years of experience in quality and regulatory affairs within CLIA/CAP-certified laboratory environments. Her career includes extensive leadership in:

• Quality management system development
• Regulatory compliance and inspections
• Start-up environments and laboratory build-outs
• Enterprise-level quality system implementation

Ms. Luckey’s leadership further reinforces CNSide’s commitment to building best-in-class quality and regulatory infrastructure.

Positioning CNSide for Accelerated Growth

Together, these strategic hires significantly enhance CNSide Diagnostics’ operational readiness as the company continues advancing its CNS oncology diagnostic solutions and preparing for expanded clinical adoption.

This leadership expansion reflects Plus Therapeutics’ broader commitment to establishing the people, systems, and governance required to support long-term growth and innovation.

Full announcement: https://lnkd.in/gnPeezS8

About CNSide Diagnostics

CNSide Diagnostics is a molecular diagnostics company dedicated to advancing precision diagnostics for cancers of the central nervous system, empowering clinicians with actionable insights for improved patient care.

#CNSideDiagnostics #PlusTherapeutics #PSTV #LeadershipAnnouncement #BiotechCareers #ClinicalDiagnostics #PrecisionMedicine #NeuroOncology #CLIA #CAP #QualitySystems #RegulatoryAffairs #HealthcareInnovation #LifeSciences